As E.U. and U.S. officials meet in New York this week for the 15th round of Transatlantic Trade and Investment Partnership (TTIP) negotiations, a new report warns of how the corporate-friendly, increasingly unpopular deal could “lock in” high drug prices and “help entrench a broken medical innovation system.”
Specifically, the analysis explains how expanding intellectual property rules and monopoly protections for medicines, which the TTIP seeks to do, is counterproductive at a time when E.U. member states and the U.S. “are facing a looming access to medicines crisis.”
According to the report:
Indeed, “Given the record level of public outrage and debate over skyrocketing medicine prices in the U.S. and Europe, it is inconceivable that a trade agreement attempts to set into stone even more pro-industry rules,” said Sophie Bloemen, co-founder of the E.U.-based Commons Network, which released Monday’s report (pdf) along with Health Action International, of the Netherlands, and U.S. watchdog group Public Citizen.
Doctors Without Borders/Médecins sans Frontières has similarly warned that the Trans Pacific Partnership (TPP)—also stalled largely due to public opposition—contains “aggressive intellectual property (IP) rules that would restrict access to affordable, lifesaving medicines for millions of people.”
SCROLL TO CONTINUE WITH CONTENT
Click Here: Putters